Researchers behind the Liquid Biopsy Core have built a low-cost microfluidic chip that aims to make DNA and RNA extraction faster, cheaper, and easier to scale for clinical studies. A microfluidic chip is a small device with tiny channels and structures that manipulate fluids in very small volumes, letting scientists handle precious biological samples with more control than many standard lab methods. In this case, the chip is designed for solid-phase extraction, a common technique that isolates genetic material by binding it to a surface while impurities are washed away. The team says the device works well for several types of DNA, including cell-free DNA (cfDNA), plasmid DNA, and genomic DNA, and can also be used to recover total RNA. According to the provided data, the chip achieves more than 85% recovery across a wide range of DNA sizes, outperforming widely used commercial kits from Qiagen and Norgen. Just as important, the chip is made from injection-molded plastic, which means it can be produced in large quantities at low cost rather than fabricated one by one with expensive lab methods. The system is also designed for automation, with a fluid-handling robot able to run multiple chips at once, making it practical for high-throughput studies. Together, those features point to a useful platform for liquid biopsy research, where scientists need reliable ways to isolate rare and fragile biomarkers from blood and other clinical samples.
A chip built for routine sample prep
The heart of the platform is a plastic extraction chip filled with micropillars, tiny post-like structures that increase surface area inside the device. More surface area gives DNA more places to bind, which helps the chip hold a relatively high genetic payload, including up to 2,000 nanograms of cell-free DNA.
That matters because sample preparation is often the quiet bottleneck in molecular testing. Even when downstream analysis is powerful, poor extraction can waste material, skew results, or miss low-abundance signals that could be clinically important.
How the extraction works
In solid-phase extraction, DNA or RNA is encouraged to stick to a surface under specific chemical conditions, then released after unwanted material has been removed. Here, the chemistry can be tuned with an immobilization buffer containing polyethylene glycol (PEG), salt such as NaCl or MgCl2, and ethanol.
By changing that buffer composition, the system can preferentially capture different DNA size ranges. That is especially useful in liquid biopsy, because the size of DNA fragments can carry biological meaning and can also influence how well a test performs.
Why cell-free DNA is a key target
Cell-free DNA is DNA that circulates outside cells, often in blood plasma, after being released from normal or diseased tissues. In cancer and other conditions, a small fraction of that material may contain clinically relevant information, which is why cfDNA has become central to noninvasive testing.
The challenge is that cfDNA is typically fragmented, dilute, and mixed with many other molecules. A method that recovers a high percentage of it across a broad size range can improve the odds of detecting meaningful biological signals without requiring larger sample volumes.
Performance and comparison to standard kits
The team reports recovery values above 85% for DNA across a large size range, and says the chip outperforms established extraction products from Qiagen and Norgen. Those commercial kits are well known in research and clinical labs, so beating them on recovery suggests this is more than just a cheaper alternative.
It is also notable that the same chip can extract total RNA, not only DNA. RNA is often more delicate than DNA, so a platform that handles both could simplify workflows for labs that want to profile multiple classes of biomarkers from the same study.
Designed for scale and automation
One of the strongest practical advantages is manufacturability. Because the chip is made from injection-molded plastic, it can be produced in high volume at low unit cost, a major benefit for large validation studies or multicenter clinical trials where consistency and supply matter.
After molding, the chip undergoes UV/O3 activation and cover plate bonding before use. In plain terms, those steps prepare the surface and seal the device, turning a mass-producible plastic part into a functional extraction tool for biological samples.
A robotic workflow for liquid biopsy samples
The extraction chips are paired with a liquid-handling robot built specifically for isolating liquid biopsy markers. The robot uses a pair of pipette tips to push and pull samples through the microfluidic channels, automating a process that would otherwise require more manual handling.
The raw material notes that the robot can process multiple chips simultaneously, with references to eight chips at once and 16 samples in one automated run. Either way, the core idea is clear: the platform is meant for parallel processing, which improves throughput and reduces operator-to-operator variability.
Beyond DNA: a broader liquid biopsy platform
The same robotic infrastructure is described as supporting chips tailored to different targets, including biological cells, extracellular vesicles, and cell-free molecules. Extracellular vesicles, or EVs, are tiny membrane-bound particles released by cells that can carry proteins and nucleic acids, making them another promising source of disease information.
That broader design matters because liquid biopsy is not a single test but a family of approaches. A shared hardware system that can switch between rare cells, EVs, and cfDNA could make a research core more flexible and lower the barrier for investigators exploring new biomarker combinations.
Why This Matters
Most breakthroughs in precision medicine do not depend on one spectacular machine; they depend on reliable, affordable tools that make good data easier to obtain. Sample extraction may sound mundane, but it is one of the most important steps in any workflow that tries to detect rare biomarkers in blood or other fluids.
If this chip delivers high recovery, low cost, and easy automation in real-world studies, it could help more labs run liquid biopsy projects without relying on expensive consumables or labor-intensive protocols. That would be valuable for academic groups, clinical trial teams, and potentially companies developing diagnostics that need reproducible sample preparation at scale.
What comes next
The platform is already positioned as a service for internal and external users, including academic and private-sector clients, which suggests it is moving beyond proof-of-concept toward routine use. The next important test will be how consistently it performs across diverse clinical samples and whether its extraction gains translate into better downstream detection of disease markers.
Still, the concept is compelling: a simple plastic chip, manufactured cheaply, tuned with straightforward chemistry, and run on an automated robot to isolate some of the most valuable molecules in modern diagnostics. In a field where scalability often determines whether a clever invention becomes a real tool, that combination could make this microfluidic system especially useful.